Association of the DRB1*16:02 with clinical features of patients with anti-NMDAR encephalitis
| With HLA-DRB1*16:02 (n=17) | Without HLA-DRB1*16:02 (n=44) | P value | |
| Age (year, mean±SD) | 22.1±11.5 | 26.9±16.8 | 0.469 |
| Gender (male:female) | 8:9 | 22:22 | 0.807 |
| BMI (median, range) | 20.8 (14.6–30.4) | 20.3 (8.3–29.1) | 0.469 |
| mRS before the treatment (median, range) | 3 (1–5) | 4 (1–5) | 0.581 |
| mRS after the treatment (median, range) | 3 (0–5) | 2 (0–5) | 0.146 |
| Decrease in mRS in response to the treatment (median, range) | 1 (0–3) | 2 (0–5) | 0.033 |
| CSF routine | |||
| CSF WBC (×106/L, median, range) | 8.0 (2–210) | 8.5 (0–142) | 0.809 |
| CSF TP (g/L, median, range) | 0.25 (0.08–2.60) | 0.31 (0.07–1.24) | 0.904 |
| CSF Glu (mmol/L, median, range) | 3.14 (2.12–4.09) | 3.24 (1.81–5.49) | 0.281 |
| CSF CL (mmol/L, median, range) | 124.0 (118.7–132.2) | 122.5 (111.0–131.0) | 0.182 |
CL, chlorine.BMI, body mass index; CSF, cerebrospinal fluid; Glu, glucose; TP, total protein; WBC, white blood cells; anti-NMDAR, anti-N-methyl-D-aspartate receptor; mRS, modified Rankin Scale.